Physician profile
Patrick Daniel Colerick
NPI 1912057373
$3,099.67
in general payments reported to CMS, 2019-2025
17 companies · $188 in 2025
The $188 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2020: $536 · 2021: $623 · 2022: $726 · 2023: $516 · 2024: $245 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $931 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $931.03 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $1,400.38 | 2020-2025 | Idose, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Alcon Vision LLC | $357.74 | 2020-2023 | Simbrinza |
| Aerie Pharmaceuticals, INC. | $238.91 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $225.71 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $189.59 | 2022-2023 | Vyzulta, Lotemax Sm, Miebo |
| Sun Pharmaceutical Industries INC. | $115.10 | 2019-2021 | |
| Allergan, INC. | $100.00 | 2019 | |
| Oyster Point Pharma, INC. | $78.24 | 2022-2024 | Tyrvaya, Ryzumvi |
| Abbvie INC. | $74.52 | 2024-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $68.79 | 2023 | Tecnis Simplicity |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $52.74 | 2020-2021 | |
| Akorn Operating Company LLC | $43.65 | 2021 | |
| Rxsight INC | $43.34 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Harrow Eye, LLC | $38.56 | 2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $25.82 | 2025 | Xdemvy |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $24.86 | 2019 | |
| Shire North American Group INC | $21.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Colerick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.